相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau et al.
BLOOD (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
Meletios A. Dimopoulos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma
David C. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Irene M. Ghobrial et al.
LANCET ONCOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Genetic variation associated with bortezomib-induced peripheral neuropathy
Reyna Favis et al.
PHARMACOGENETICS AND GENOMICS (2011)
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA
Debra L. Barton et al.
SUPPORTIVE CARE IN CANCER (2011)
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay et al.
BLOOD (2010)
Sequence variation at multiple loci influences red cell hemoglobin concentration
Luanne L. Peters et al.
BLOOD (2010)
Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
Craig B. Reeder et al.
BLOOD (2010)
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Jeffrey A. Zonder et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
Shaji Kumar et al.
BLOOD (2010)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen et al.
BLOOD (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Lawrence R. Dick et al.
DRUG DISCOVERY TODAY (2010)
Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice
Jordi Bruna et al.
EXPERIMENTAL NEUROLOGY (2010)
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
Bilal Mohty et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Jean-Luc Harousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients
Roser Velasco et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Michel Delforge et al.
LANCET ONCOLOGY (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
M. Q. Lacy et al.
LEUKEMIA (2010)
Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland
I. Hrusovsky et al.
ONCOLOGY (2010)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Heinz Ludwig et al.
BLOOD (2009)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson et al.
BLOOD (2009)
High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response
Marc Remke et al.
BLOOD (2009)
Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia
David C. Rees et al.
BLOOD (2009)
Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration
Manik C. Ghosh et al.
BLOOD (2009)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
Joseph R. Mikhael et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
Michele Cavo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2009)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo et al.
BLOOD (2008)
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells - A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition
Marianne S. Poruchynsky et al.
CELL CYCLE (2008)
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
Marie von Lilienfeld-Toal et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma
S. Vincent Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
From bench to bedside: A case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol
Leslie A. Colvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy
Vinay Chaudhry et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro
Vilmos Csizmadia et al.
NEUROTOXICOLOGY (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board
Joseph D. Tariman et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2008)
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Henk M. Lokhorst et al.
HAEMATOLOGICA (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma
Naciye Demirel Yildirim et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale
Guido Cavaletti et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2007)
Neuropathy in multiple myeloma treated with thalidomide - A prospective study
R. Plasmati et al.
NEUROLOGY (2007)
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
K. Zervas et al.
ANNALS OF ONCOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat
Guido Cavaletti et al.
EXPERIMENTAL NEUROLOGY (2007)
Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies
A. Krarup-Hansen et al.
BRAIN (2007)
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
Ashraf Badros et al.
CANCER (2007)
Acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy - A short review
Domenico De Grandis
CNS DRUGS (2007)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson et al.
BLOOD (2006)
Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
Linda Mileshkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Evidence for direct axonal toxicity in vincristine neuropathy
Angelica Silva et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
A Glasmacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy
FH Hausheer et al.
SEMINARS IN ONCOLOGY (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
JR Berenson et al.
CANCER (2005)
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20
TJ Postma et al.
EUROPEAN JOURNAL OF CANCER (2005)
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Neurological aspects of multiple myeloma and related disorders
A Dispenzieri et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2005)
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
MA Dimopoulos et al.
ANNALS OF ONCOLOGY (2003)
Cerebellitis in an adult with abnormal magnetic resonance Imaging findings prior to the onset of ataxia
KL Gruis et al.
ARCHIVES OF NEUROLOGY (2003)
Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid
C Gedlicka et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
P Sonneveld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
分享论文
